Michael J Elliott, MBBS, PhD, FRACP

    Dr Elliott is a physician-scientist, drug developer and biotech pioneer. He earned his medical degree (MBBS) and PhD from the University of Adelaide, Australia, and was elected a Fellow of the Royal Australasian College of Physicians.  His early scientific work at the University of Adelaide and at the Walter and Eliza Hall Institute in Melbourne included studies on the biology and receptor interactions of the hemopoietic growth factors, GM-CSF and IL-3.  At the Kennedy Institute of Rheumatology in London, he worked on the first clinical trials of anti-TNF therapy in rheumatoid arthritis and was lead author on several acclaimed publications that provided first clinical validation for this radical new approach to therapy.  Dr Elliott authored many peer-reviewed journal articles, reviews and book chapters in the field of cytokine immunology and protein therapeutics.

    His pharmaceutical and biotech career spans 23 years working in various R&D roles, including 17 years at Centocor/Janssen/Johnson & Johnson.  At Centocor, he held the position of Senior Vice President, Immunology, and led the clinical development of Centocor’s monoclonal antibody (mAb) products in immune and inflammatory disorders, including the anti-TNF mAb infliximab (REMICADE) developed for rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other inflammatory indications, and the follow-on anti-TNF mAb, golimumab (Simponi), developed in a range of rheumatic diseases.  His group also led clinical development of the first in class anti-IL-12/23 mAb, ustekinumab (Stelara) for the treatment of psoriasis. More recently, Dr Elliott served as General Manager and Site Head at TransForm Pharmaceuticals, a J&J company focused on high throughput drug formulation, and as a member of the J&J Corporate Office of Science and Technology. In 2012, Dr Elliott transitioned to the role of Janssen Entrepreneur in Residence at Polaris Partners, and joined the newly established J&J Boston Innovation Center as VP, Immunology Scientific Innovation, where he built a portfolio of early stage academic partnerships and biotech investments of interest to Janssen Immunology.

    Dr Elliott retired from full-time work in 2019, and now supports the local life science ecosystem in his adopted state of Rhode Island and more broadly within New England, including roles with industry, academic and government organizations.